000			05293namaa22004331i 4500
003			OSt
005			20250522113200.0
008			250511s2024 ua a|||fr|m|| 000 0 eng d
040			_aEG-GICUC _beng _cEG-GICUC _dEG-GICUC _erda
041	0		_aeng _beng _bara
049			_aDeposit
082	0	4	_a616.99419
092			_a616.99419 _221
097			_aPh.D
099			_aCai01.11.18.Ph.D.2024.Am.I.
100	0		_aAmr Mohammed Abd El Fattah, _epreparation.
245	1	4	_aThe impact of the prevalence of glutathione S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib) / _cBy Amr Mohammed Abd El Fattah; Under Supervision of Prof. Dr. Nehad Mohammed Tawfeek, Dr. Mohamed Ahmed Fateen, Dr. Ibrahim Ahmed Ibrahim Abdalgawad /
246	1	5	_aتأثير انتشار الجلوتاثيون S- ترانسفيراز تعدد الأشكال علي الإستجابة من المرضي المصريين المصابين بسرطان الدم النخاعى المزمن الى الخط الأول من مثبطات التيروزين كيناز(ايماتينيب) /
264		0	_c2024.
300			_a84 pages : _billustrations ; _c25 cm. + _eCD.
336			_atext _2rda content
337			_aUnmediated _2rdamedia
338			_avolume _2rdacarrier
502			_aThesis (Ph.D)-Cairo University, 2024.
504			_aBibliography: pages 79-84.
520			_aRationale: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Tyrosine kinase inhibitors (TKIs) had significantly changed the treatment landscape, improving outcomes for patients with CML treatment. First generation TKIs imatinib had improved the 8-years overall survival rate from 20 to 87%. Four generations of TKIs were approved and commonly used for the treatment of CML. The occurrence of CML is controlled by a set of factors such as exposure to environmental carcinogens and the ability to eliminate toxic substances. Resistance to tyrosine kinase inhibitors constitutes a big challenge in the treatment of patients with CML. This resistance could be linked to glutathione transferase activity. Several studies in literature studied the impact of glutathione over CML patients as risk of both susceptibility, treatment resistance and poor response. Purpose: This study aims to evaluate the presence of Glutathione transferase polymorphism on CML patients and the impact of glutathione s polymorphism on the molecular response BCR-ABL (IS %) on CML patients on the first line tyrosine kinase inhibitor (imatinib) Methodology: The study included 50 patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor imatinib were recruited from outpatient hematology clinic at kasr El Einy hospital and followed over the period from October 2021 to October 2023. The patients were investigated for routine laboratory investigations including complete blood picture, liver functions, renal functions, molecular BCR-ABL (IS %) and glutathione s polymorphism Results: The study results show correlation between molecular response BCR- ABL (IS %) of different groups of the study and severity of anemic manifestations with statistically significant difference of p value 0.023. The results of the study show no correlation between Glutathione S polymorphism and molecular response of CML cases among study group as no statistically significance difference with p value 0.94 so the study shows no impact of the GSP1 on the molecular response of the patients
520			_aتهدف دراستنا إلى تقييم انتشار و تأثير تعدد أشكال الجلوتاثيون على الاستجابة الجزيئية لدى المرضى المصريين بسرطان الدم الميلودي المزمن للجيل لأول من مثبطات التيروزين كيناز (ايماتينيب). وجدت الدراسة وجود علاقة ذات دلالة إحصائية بين الاستجابة الجزيئية و حدة أعراض فقر الدم بين المجموعات المختلفة حيث وجدنا تحسن في أعراض فقر الدم مع تحسن الاستجابة الجزيئية مع عدم وجود تأثير لتعدد أشكال الجلوتاثيون S على الاستجابة الجزيئية في حالات سرطان الدم النخاعي المزمن على إيماتينيب
530			_aIssued also as CD
546			_aText in English and abstract in Arabic & English.
650		7	_aLeukemia _2qrmak
653		0	_aCML (Chronic myeloid leukemia) _aImatinib resistance _aTKIs (Tyrosine kinase inhibitor ) _aGSTs (Glutathione transferases)
700	0		_aNehad Mohammed Tawfeek _ethesis advisor.
700	0		_aMohamed Ahmed Fateen _ethesis advisor.
700	0		_aIbrahim Ahmed Ibrahim Abdalgawad _ethesis advisor.
900			_b01-01-2024 _cNehad Mohammed Tawfeek _cMohamed Ahmed Fateen _cIbrahim Ahmed Ibrahim Abdalgawad _UCairo University _FFaculty of Medicine _DDepartment of Internal Medicine
905			_aNourhan _eEman Ghareb
942			_2ddc _cTH _e21 _n0
999			_c172009